The prognostic significance of apical lymph node metastasis in patients with high-risk stage III colon cancer

Kenichi Ishii¹, Jun Watanabe¹, Kouki Goto¹, Yusuke Suwa¹, Kazuya Nakagawa², Hirokazu Suwa³, Mayumi Ozawa², Atsushi Ishibe², Chikara Kunisaki¹ & Itaru Endo²

The effect of apical lymph node (APN) metastasis on the prognosis of colon cancer is unknown. The present study investigated the impact of APN metastasis on the prognosis of the patients with high-risk stage III colon cancer. This retrospective multi-institutional study included patients with pathological high-risk stage III colon cancer who underwent surgery between April 2009 and December 2014. Clinicopathological factors were examined by univariate and multivariate analyses to clarify independent risk factors for overall survival (OS) and relapse-free survival (RFS). A total of 185 patients were collected. The 5-year OS rates of patients with and without APN metastasis were 35.0% and 72.1%, respectively (p = 0.0014). The 5-year RFS rates of patients with and without APN metastasis was 16.2% and 57.2%, respectively (p = 0.0002). The rate of distant metastasis in patients with APN metastasis was significantly higher than that in patients without APN metastasis (68.8% vs. 36.7%, p = 0.012). The univariate analysis revealed that the differentiation, lymph node ratio, and APN metastasis were significantly associated with 5-year OS, and the preoperative CEA and CA19-9 levels and APN metastasis were significantly associated with 5-year RFS. The multivariate analysis showed that APN metastasis was an independent risk factor for 5-year OS and RFS. APN metastasis may be independently associated with the prognosis of patients with high-risk Stage III colon cancer.

Lymph node metastasis in colon cancer is an important indicator of the need for postoperative adjuvant chemotherapy¹ and accurate classification is needed to predict the prognosis of such patients. The American Joint Committee on Cancer (AJCC) staging system and the Union for International Cancer Control (UICC) TNM classification 8th edition recommend the collection of at least 12 lymph nodes for an accurate diagnosis, and lymph node metastasis is categorized completely by number, rather than by location. This classification is simple and easy to understand and has therefore been widely accepted around the world.

However, the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma (JCCRC) defines the classification of lymph node metastasis, including information on the number and anatomic location of metastatic lymph nodes; in particular, it places much emphasis on the apical lymph nodes (APNs) around the root of the main feeding blood vessels, and APN metastasis is defined as N3 according to the JCCRC².

In recent years, the importance of APN metastasis for determining the prognosis of colon cancer patients has been debated. The integration of information on APN metastasis into the TNM classification reportedly improves the accuracy of the prognostic prediction of stage III colon cancer patients³, and Kang et al. suggested that APN metastasis should be considered a predictive factor for systematic recurrence, especially para-aortic nodal recurrence⁴. According to some reports, APN metastasis is an independent risk factor for the prognosis⁵–¹⁰. However, others authors have reported that APN metastasis does not affect the prognosis¹¹,¹²; thus, whether or not APN metastasis influences the overall survival (OS) and relapse-free survival (RFS) rates of patients with colorectal cancer remains unclear. The number of metastatic lymph nodes undoubtedly plays an important role in accurate staging; however, information on the anatomic location of metastatic lymph nodes is also likely an important factor for predicting the prognosis. APN involvement has often been reported to be an independent

¹Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, 4-57, Urafune-cho, Minami-ku, Yokohama 232-0024, Japan. ²Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. ³Department of Surgery, Yokosuka Kyosai Hospital, Yokosuka, Japan. ⁴email: jun0926@yokohama-cu.ac.jp
prognostic factor in colorectal cancer\textsuperscript{5-10,13}; thus, the anatomic location of metastatic lymph nodes may complement the UICC staging system\textsuperscript{3}.

In addition, the period of adjuvant chemotherapy for stage III colorectal cancer patients has recently been attracting attention. The International Duration Evaluation of Adjuvant Chemotherapy (IDEA collaboration) project suggested that stage III can be divided into T1-3N1 as a low-risk group and T1-3N2 or T4N1-2 as a high-risk group, and although this meta-analysis failed to prove the non-inferiority of 3-month vs. 6-month adjuvant chemotherapy for patients with stage III colon cancer in terms of OS, there was only a 0.4% difference in 5-year OS between the 2 groups\textsuperscript{14}. Furthermore, among high-risk stage III patients who received adjuvant chemotherapy with capecitabine and oxaliplatin (CAPOX), there was only 1% difference in the 5-year OS rates of patients who received a 3-month regimen and those who received a 6-month regimen; thus, the report supported the 3-month administration of adjuvant CAPOX for most stage III colon cancer patients. However, whether or not three months of CAPOX therapy is adequate for patients with APN metastasis, whose prognosis has been said to be especially poor, is unclear.

Differences in patient background characteristics among reports may be the reason for the lack of clarity regarding whether or not APN metastasis affects the prognosis of colon cancer patients. We therefore focused on high-risk stage III patients in the present study. The present study investigated the influence of APN metastasis on the prognosis of patients with high-risk stage III colon cancer.

Methods
This was a multicenter, retrospective study of patients with colon cancer who underwent surgery at our three institutions from April 2009 to December 2014. This study protocol was approved by the Ethics Advisory Committee of Yokohama City University Medical Center and the institutional review board of each participating hospital before the study was initiated. Yokohama City University Medical Center, Yokohama City University Hospital, and Yokosuka Kyosai Hospital participated in this study.

Patient data were collected from clinical reports from each institution. In order to align the patient backgrounds, the inclusion criteria were T1-3N2 or T4N1-2 in high-risk stage III patients diagnosed based on operative findings and the examination of the resected specimen. The objects were primary cancer of the cecum and ascending, transverse, descending, and sigmoid colon or rectosigmoid region, similar to the adjuvant chemotherapy for colon cancer with high evidence (ACHIEVE) trial, which is an IDEA project\textsuperscript{15}. The exclusion criteria were multiple malignant tumors without surgical resection, recurrent cases, cases that did not undergo curative resection, and cases with distant metastasis or emergent surgery. There were 603 patients who underwent radical operations and who were diagnosed with stage III colorectal cancer according to the TNM classification (UICC) based on a postoperative histopathological examination, and there were 185 applicable patients diagnosed with high-risk stage III disease (T4, N2, or both). These patients were classified according to the absence or presence of APN metastasis and their background characteristics and prognostic factors were examined.

Surgery and adjuvant chemotherapy. All patients underwent D3 dissection, including dissection of the APNs. The right-sided colon was defined as the part from the cecum to the splenic flexure of the transverse colon, and the boundary of the APNs was defined as the left margin of the superior mesenteric vein. The left-sided colon was defined as the part from the descending colon to the rectosigmoid colon, and the lymph nodes around the root of the inferior mesenteric artery on the ventral side were excised and defined as APNs. Postoperative chemotherapy based on 5-fluorouracil was considered for all stage III patients. The attending doctors decided whether or not to perform postoperative chemotherapy based on the general condition and compliance of colon cancer patients.

Pathologic examinations. The regional lymph nodes were individually removed from the specimen immediately after surgery manually by the surgeons and were classified as pericolic lymph nodes, intermediate lymph nodes, or APNs. They were pathologically evaluated by the pathologists in the gastrointestinal tract according to the UICC diagnostic criteria. The lymph node ratio was defined as the number of metastatic lymph nodes divided by the total number of dissected lymph nodes.

Follow-up. Postoperative surveillance methods included collection of the medical history, physical examinations, laboratory studies (including serum carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 [CA19-9] every three months), and CT examinations of the chest to abdomen and pelvis every six months for the first three years; follow-up was then performed every six months for the next two years. Colonoscopy was performed in the first, third, and fifth year after the operation. The diagnosis of recurrence was made using clinical, radiographic, and histological methods. Local recurrence was defined as tumor recurrence around the anastomotic site or the region of the primary operation. Distant metastasis was defined as metastasis to the distant organs with hematogenous or lymphogenous spreading, diffuse peritoneal seeding, or metastasis in all other nonregional lymph nodes, such as the paraaortic lymph nodes.

Statistical analyses. Categorical variables are reported as numbers and percentages, and continuous variables are reported as medians and interquartile ranges (IQRs). The following continuous variables were divided into 2 categories for the analyses: age (≥ 65 years, < 65 years), BMI (≥ 25 kg/m\textsuperscript{2}, < 25 kg/m\textsuperscript{2}), preoperative CEA level (≥ 5 ng/ml, < 5 ng/ml), preoperative CA19-9 level (≥ 37 ng/ml, < 37 ng/ml), tumor size (≥ 50 mm, < 50 mm), and lymph node ratio (≥ 0.15, < 0.15). Five-year OS was defined as the time from the first treatment to death for any reason within 5 years, or the last follow-up examination. RFS was defined as the time from the initial treatment to the date on which recurrence or distant metastasis was diagnosed, or the last follow-up examination.
Statistical analyses were performed using the JMP Pro software program (version 15.0.0, SAS Institute Inc., Cary, NC, USA). The differences in variables for each category were analyzed by Pearson's chi-squared test, Fisher's test, or Wilcoxon's rank sum test, and the 5-year OS and RFS rates were shown using the Kaplan–Meier method, with the log-rank test used to compare prognostic factors and survival curves. A Cox regression analysis was used to determine the hazard ratio. P values of < 0.05 were considered to indicate statistical significance. A Cox proportional hazards model was used to identify independent prognostic risk factors for 5-year OS and RFS.

Results
Table 1 shows the clinicopathological data of the patients with high-risk stage III colon cancer. The median age was 71 (IQR: 61–78) years, 63.2% (117/185) of the patients were male and 36.8% (68/185) of the patients were female. The median BMI was 22 (19.9–24.3). The median preoperative serum CEA level was 5.0 (IQR: 2.6–11.1) ng/mL, and the median CA19-9 level was 12 (IQR: 6–26.5) ng/mL. The median maximum tumor size was 45 (IQR: 35–60) mm. Right-sided colon cancer was seen in 38.4% (71/185) of the patients and left-sided colon cancer was seen in 61.6% (114/185) of the patients. A laparoscopic approach was used for treatment in 55.1% (102/185) of the cases. On histological examination, 27 tumors were poor or mucinous, and 158 tumors were well-differentiated or moderately differentiated adenocarcinoma. The median number of retrieved lymph nodes was 25 (IQR: 18–33), and the median number of metastatic lymph nodes was 4 (IQR: 1–5). Postoperative adjuvant chemotherapy was administered to 62.16% (115/185) of the patients.

The patients with high-risk stage III colorectal cancer were divided into two groups according to the presence or absence of APN metastasis and their background characteristics were compared. A total of 8.6% (16/185) of patients were positive for APN metastasis. The number of metastatic lymph nodes in patients with APN metastasis was significantly greater than that in the patients without APN metastasis (8 vs. 3, p < 0.0001), as was the lymph node ratio (0.3 vs. 0.14, p < 0.0001). Consequently, a significant proportion of patients with APN metastasis were diagnosed with pN2. The group with APN metastasis had a significantly higher recurrence rate than the group without APN metastasis. The recurrence rate with APN metastasis vs. without APN metastasis was 8 vs. 3, p < 0.0001, and while there was no significant difference in the rate of local recurrence (6.25% vs. 4.14%, p = 0.692), there was a significant difference in the rate of distant metastasis (68.75% vs. 36.68%, p = 0.012), with no significant difference noted between the two groups in the rates of liver, lung, and local site recurrence. The liver (31.3%) was the most common site of distant metastasis in high-risk stage III patients with APN metastasis, as noted in a previous report.

Regarding the operative results, there was no significant difference in the operation time, amount of intraoperative bleeding, open or laparoscopic approaches, or complications. The patients were followed up for a median 58 (IQR: 37–69) months, and the 5-year OS and RFS rates were 69.4% and 54.0%, respectively. The OS differed significantly between the groups; the 5-year OS rates of patients with and without APN metastasis were 35.0% and 72.1%, respectively (p = 0.0014, Fig. 1). The RFS also differed significantly between the groups; the RFS of the patients with and without APN metastasis was 16.2% and 57.2%, respectively (p = 0.0002, Fig. 2).

The distribution of potential prognostic factors according to the absence or presence of APN metastasis is displayed in Table 2. The univariate analysis indicated that the factors associated with the 5-year OS of the patients were differentiation, lymph node ratio, and APN metastasis. The factors associated with 5-year RFS were the preoperative CEA, CA19-9 level, and APN metastasis. In the univariate analysis, the common risk factor for 5-year OS and RFS was APN metastasis (Table 3).

A multivariate Cox regression analysis identified the following independent risk factors for poor 5-year OS: APN metastasis (hazard ratio[HR] = 3.3; 95% confidence interval[CI] = 1.4–7.4, p = 0.0052) and histologically poor or mucinous tumor (HR = 3.0, 95% CI = 1.5–5.7, p = 0.0013), and those for short RFS were APN metastasis (HR = 2.9, 95% CI = 1.6–5.4, p = 0.0008) and serum CEA (HR = 1.7, 95% CI = 1.0–2.6, p = 0.035) after adjustment for confounding variables. In the multivariate logistic regression analysis, APN metastasis was statistically the strongest predictor of a poor prognosis in patients with high-risk Stage III colon cancer.

Discussion
The influence of APN metastasis on the prognosis and recurrence of patients with colon cancer remains controversial. The number of metastatic lymph nodes is one of the most important factors in determining the need for adjuvant chemotherapy for colorectal cancer patients, and it is also an important factor in predicting the prognosis. The AJCC and UICC TNM classification classify the pN stages based on the number of metastatic lymph nodes; this system is easy to understand and is used in most of the world. Suzuki et al. showed that the number of metastatic lymph nodes predicted the prognosis better than the distribution of metastatic lymph nodes in patients with stage III colon cancer, and some authors have shown no marked difference in the survival of patients with stage N2 disease and those with APN metastasis.

In contrast, some reports have suggested the influence of the distribution of metastatic lymph nodes on the prognosis. Huh et al. proposed the concept that the metastatic lymph node distribution is an independent prognostic factor for both OS and disease-free survival in patients with sigmoid colon and rectal cancer. Chen et al. showed that the T3 and T4 stages and poor differentiation were significant correlated with APN metastasis in 578 colorectal cancer patients. Reportedly, the greater the number of metastatic lymph nodes in patients with APN metastasis, the poorer their prognosis. In the present analysis, the number of metastatic lymph nodes increased in the presence of APN metastasis, thus, the proportion of N2 cases increased. In addition, the 5-year OS and RFS rates of high-risk stage III patients with APN metastasis were significantly worse than those of patients without APN metastasis. The results of the Cox regression analysis in this study showed that APN metastasis is an independent risk factor for RFS, and it is meaningful to distinguish APN metastasis from other lymph node metastases.
| Variable                      | APN positive | APN negative | Total | P value |
|------------------------------|--------------|--------------|-------|---------|
| Age (years) *                | 72 (58–78)   | 71 (61–78)   | 71 (61–78) | 0.717   |
| Male sex                     | 13 (81.3)    | 104 (63.5)   | 117 (63.2) | 0.118   |
| BMI*                         | 20.7(19.5–23.7) | 22.3(19.9–24.3) | 22 (19.9–24.3) | 0.318   |
| PS                           | 0.500        |              |       |         |
| 0                            | 15 (93.8)    | 150 (88.7)   | 165 (89.2) |         |
| 1                            | 1 (6.2)      | 16 (9.5)     | 17 (9.2)   |         |
| 2                            | 0 (0)        | 1 (0.6)      | 1 (0.5)    |         |
| 3                            | 0 (0)        | 2 (1.2)      | 2 (1.1)    |         |
| CEA*                         | 4.2 (2.7–9.3) | 4.9 (2.5–11.2) | 5.0 (2.6–11.1) | 0.401   |
| CA19-9 *                     | 12 (6.0–52)  | 12 (6.2–26)  | 12 (6.0–26.5) | 0.848   |
| Tumor size, mm               | 57.5 (30–83) | 45 (35–60)   | 45 (35–60) | 0.237   |
| Location                     |              |              | 0.187 |         |
| Cecum                        | 0 (0)        | 18 (100)     | 18 (9.7)   |         |
| Ascending colon              | 4 (25.0)     | 24 (14.2)    | 28 (15.1)  |         |
| Transverse colon             | 4 (25.0)     | 21 (11.4)    | 25 (13.5)  |         |
| Descending colon             | 0 (0)        | 9 (5.3)      | 9 (4.9)    |         |
| Sigmoid colon                | 3 (18.8)     | 62 (36.7)    | 65 (35.1)  |         |
| Rectosigmoid                 | 5 (31.3)     | 35 (20.7)    | 40 (21.6)  |         |
| Right-sided colon            | 8 (50.0)     | 63 (37.3)    | 71 (38.4)  | 0.317   |
| Left-sided colon             | 8 (50.0)     | 106 (62.7)   | 114 (61.6) |         |
| Differentiation              |              |              | 0.993 |         |
| Well                         | 4 (25.0)     | 44 (26.0)    | 48 (25.9)  |         |
| Moderate                     | 10 (62.5)    | 100 (59.2)   | 110 (59.5) |         |
| Poor                         | 1 (6.3)      | 12 (7.1)     | 13 (7.0)   |         |
| Mucinous                     | 1 (6.3)      | 13 (7.7)     | 14 (7.6)   |         |
| pT category                  |              |              | 0.552 |         |
| T1                           | 0 (0)        | 2 (1.2)      | 2 (1.1)    |         |
| T2                           | 1 (6.3)      | 4 (2.4)      | 5 (2.7)    |         |
| T3                           | 5 (31.3)     | 39 (20.7)    | 40 (21.6)  |         |
| T4                           | 10 (62.5)    | 128 (75.7)   | 138 (74.6) |         |
| pN category                  |              |              | 0.0139 |         |
| N1                           | 3 (18.8)     | 87 (51.5)    | 90 (48.6)  |         |
| N2                           | 13 (81.3)    | 82 (48.5)    | 95 (51.35) |         |
| Harvested LNs *              | 27 (22.5–33.5) | 24 (18–32)   | 25 (18–33) | 0.683   |
| Metastatic LNs *             | 8 (5.8–11.8) | 3 (1–5)      | 4 (1–5)    | <0.001   |
| LN ratio *                   | 0.3 (0.2–0.4) | 0.14(0.06–0.22) | 0.14(0.07–0.25) | <0.001 |
| Ly +                         | 8 (50.0)     | 128 (75.7)   | 136 (73.5) | 0.026   |
| V +                          | 13 (81.3)    | 123 (72.8)   | 136 (73.5) | 0.463   |
| Type of surgery              |              |              | 0.666 |         |
| Laparoscopic                 | 8 (50.0)     | 94 (55.6)    | 102 (55.1) |         |
| Open                         | 8 (50.0)     | 75 (44.4)    | 83 (44.9)  |         |
| Operation time(min)          | 199.5 (183–223) | 181 (148–214) | 183 (149–216) | 0.112   |
| Bleeding(ml)                 | 45 (9–426)   | 47.5 (10–150) | 47.5(10–161) | 0.580   |
| Complication b               | 4 (25)       | 41 (24.3)    | 45 (24.3)  | 0.948   |
| Adjuvant chemotherapy        | 9 (56.3)     | 106 (62.7)   | 115 (62.2) | 0.610   |
| Recurrence                   | 12 (75.0)    | 69 (40.8)    | 81 (43.8)  | 0.009   |
| Local                        | 1 (6.3)      | 7 (4.1)      | 8 (4.3)    | 0.692   |
| Distant sites                | 11 (68.8)    | 62 (36.7)    | 73 (39.5)  | 0.012   |
| Liver                        | 5 (31.3)     | 26 (15.4)    | 31 (16.8)  | 0.104   |
| Lung                         | 3 (18.8)     | 11 (6.5)     | 14 (7.6)   | 0.077   |
| Peritoneal                   | 2 (12.5)     | 18 (10.7)    | 20 (10.8)  | 0.820   |
| Other sites                  | 2 (12.5)     | 8 (4.7)      | 10 (5.4)   | 0.189   |

Table 1. Correlation between the APN metastasis and the clinicopathologic factors. Values in parentheses are percentages, unless indicated otherwise; *Values are median (IQR: first quartile—third quartile). BMI: body mass index, calculated as weight in kilograms divided by height in meters squared, PS: performance status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, LN: lymph node, LN ratio: the number of metastatic lymph nodes divided by the total number of dissected lymph nodes, Ly+: lymphatic involvement, V+: vascular invasion. b Clavien-Dindo classification grade ≥ II, within 30 days after surgery.
APN metastasis reportedly represents a local—rather than systemic—problem\textsuperscript{18,20}. In contrast, Kang et al. reported that colorectal cancer patients with APN metastasis had a much higher rate of systemic recurrence rate than those without APN metastasis (48.5% vs. 20.8%, p < 0.001), whereas there the local recurrence rates of the groups did not differ to a statistically significant extent\textsuperscript{4}. Huh et al. revealed that the 5-year OS rate of stage IV patients with left-sided colorectal cancer was not significantly different from that of stage III patients with APN metastasis (45% vs. 40%, respectively, p = 0.761)\textsuperscript{6}. Our analysis showed that high-risk stage III patients with APN metastasis had a poor prognosis, which was in line with previous reports\textsuperscript{3–10}. The 5-year OS rate in high-risk stage III patients with APN metastasis was only 35.0%, and the distant metastasis rate of high-risk stage III patients with APN metastasis was significantly higher than that of patients without APN metastasis (68.8% vs. 36.7%, respectively; p = 0.0012). These results suggest that APN metastasis is an indication of systemic disease rather than a regional problem. Therefore, distinguishing APN metastasis from other lymph node metastasis may benefit patients with high-risk stage III colon cancer, as information concerning APN metastasis will help predict the OS and RFS according to patient risk factors and may help guide the administration of adjuvant chemotherapy. APN metastasis was diagnosed in 8.6% of our patients, and the rate was similar to that of previous reports; the incidence of lymph node metastasis at the root of the inferior mesenteric artery was reported to be 0.3–13.5\%\textsuperscript{6,11,12} in patients with left-sided colorectal cancer and 3.0–17.1\%\textsuperscript{5,10,14} in patients with right-sided colon cancer. In this analysis, only 6 of 16 patients (37.5\%) were diagnosed with APN metastasis by preoperative CT; thus, it may be difficult to diagnose APN metastasis preoperatively. Therefore, it is meaningful to perform high-level ligation and D3 dissection for patients with advanced cancer, even if there is no obvious APN metastasis on preoperative CT.

**Figure 1.** Kaplan–Meier curves showing the 5-year OS rates of high-risk stage III patients with and without APN metastasis. Outcomes of patients with high-risk stage III colorectal cancer. The 5-year OS rates of patients with and without APN metastasis were 35.0% and 72.1%, respectively (p = 0.0014). OS: overall survival, APN: apical lymph node.

**Figure 2.** Kaplan–Meier curves showing the 5-year RFS rates of high-risk stage III patients with and without APN metastasis. The outcomes of patients with high-risk stage III colorectal cancer. The RFS rates of patients with and without APN metastasis were 16.2% and 57.2%, respectively (p = 0.0002). RFS: relapse free survival, APN: apical lymph node.
As another topic, it was reported that elevated postoperative CEA—especially within the first 12 months after surgery—is an important indicator of recurrence of colon cancer. In this study, the blood levels of CEA were followed for 5 years, which helped to indicate when to perform additional tests to detect the recurrence of colorectal cancer. Therefore, it is thought that routine postoperative CEA measurement should be recommended.

According to a large-scale recent study, the HRs for 5-year OS and RFS high-risk stage III patients who received 6-month and 3-month postoperative adjuvant chemotherapy with CAPOX only showed a slight difference, suggesting that 3-month postoperative adjuvant chemotherapy is acceptable. In our institutions, patients diagnosed with stage III disease are considered for adjuvant chemotherapy with 5-fluorouracil based on their performance status, social background, and personal wishes. Even though the adjuvant chemotherapy regimens in our study were not unified and consisted of several regimens (e.g., CAPOX, fluorouracil, leucovorin and oxaliplatin[modified FOLFOX6], S-1 and oxaliplatin[SOX], and uracil and tegafur plus leucovorin[UFT/LV], and despite the fact that the percentage of high-risk stage III patients with APN metastasis who received adjuvant chemotherapy was relatively low (56.3%) in comparison to a previous study (50%-93.9%), the high-risk stage III patients with APN metastasis still had a significantly worse prognosis than those without APN metastasis, and a multivariate analysis showed that APN metastasis was independently associated with a worse prognosis. Therefore, APN metastasis should be distinguished from metastasis of other lymph nodes, and it may be best to avoid shortening the postoperative adjuvant chemotherapy regimen, especially for high-risk stage III patients with APN metastasis. Furthermore, it was reported that even though patients with APN metastasis received standard FOLFOX adjuvant chemotherapy, they had poorer disease-free survival and OS in comparison to those without APN metastasis; thus, future studies should explore the optimum adjuvant chemotherapy regimen for patients with APN metastasis.

The present study was associated with some limitations. First, this was a retrospective study, and the number of patients with APN metastasis was very small.

### Table 2. Univariate analyses of risk factors for 5-year OS and RFS. OS: overall survival, RFS: relapse free survival, HR: hazard ratio, CI: confidence interval, BMI: body mass index, calculated as weight in kilograms divided by height in meters squared, PS: performance status, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, pT: pathological T stage, pN: pathological N stage, LN: lymph node, LN ratio: the number of metastatic LN divided by that of retrieved LN, APN: apical lymph node.

| Variables                  | 5-year OS |          |          |          | 5-year OS |          |          |          |
|----------------------------|-----------|----------|----------|----------|-----------|----------|----------|----------|
| Age, ≥ 65 years            | 1.3       | 0.72–2.4 | 0.37     | 0.85     | 0.54–1.3  | 0.47     |
| Sex, Male                  | 1.3       | 0.88–1.8 | 0.21     | 1.2      | 0.78–1.9  | 0.37     |
| BMI ≥ 25                   | 1.2       | 0.64–2.4 | 0.54     | 1.0      | 0.59–1.8  | 0.93     |
| PS, ≥ 1                    | 1.1       | 0.47–2.6 | 0.81     | 0.68     | 0.29–1.6  | 0.36     |
| CEA, ≥ 5 ng/dl             | 1.6       | 0.89–2.7 | 0.12     | 1.8      | 1.1–2.8   | 0.011    |
| CA19-9, ≥ 37 ng/dl         | 1.8       | 0.96–3.3 | 0.07     | 1.7      | 1.0–2.8   | 0.047    |
| Tumor size, ≥ 50 mm        | 1.2       | 0.71–2.1 | 0.46     | 1.3      | 0.82–2.0  | 0.28     |
| Location, Right-side       | 1.2       | 0.68–2.1 | 0.53     | 1.1      | 0.67–1.7  | 0.82     |
| Differentiation, poorly or | 2.8       | 1.5–5.2  | 0.002    | 1.4      | 0.77–2.5  | 0.28     |
| mucinous                  |
| pT, T4                     | 1.3       | 0.66–2.5 | 0.46     | 1.5      | 0.87–2.6  | 0.15     |
| pN, N2                     | 1.2       | 0.68–2.0 | 0.57     | 1.1      | 0.72–1.7  | 0.62     |
| LN ratio, ≥ 0.15           | 2.0       | 1.1–3.5  | 0.019    | 1.5      | 0.95–2.3  | 0.086    |
| Lymphatic involvement,     | 1.1       | 0.56–2.0 | 0.88     | 0.76     | 0.47–1.2  | 0.25     |
| vascular invasion          | 1.4       | 0.70–2.6 | 0.37     | 1.4      | 0.82–2.3  | 0.24     |
| APN metastasis             | 3.2       | 1.5–6.8  | 0.003    | 3.0      | 1.6–5.6   | <0.001   |
| Adjuvant chemotherapy      | 0.64      | 0.37–1.1 | 0.11     | 0.69     | 0.44–1.1  | 0.10     |

### Table 3. Multivariate analyses of risk factors for 5-year OS and RFS. OS: overall survival, RFS: relapse free survival, HR: hazard ratio, CI: confidence interval, CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9, LN ratio: the number of metastatic LN divided by that of retrieved LN, APN: apical lymph node.

| Variables                  | 5-year OS |          |          |          | 5-year OS |          |          |          |
|----------------------------|-----------|----------|----------|----------|-----------|----------|----------|----------|
| CEA, ≥ 5 ng/dl             | 1.7       | 1.0–2.6  | 0.035    |
| CA19-9, ≥ 37 ng/dl         | 1.3       | 0.77–2.2 | 0.32     |
| Differentiation, poorly or | 3.0       | 1.5–5.7  | 0.0013   |
| mucinous                  |
| LN ratio, ≥ 0.15           | 1.5       | 0.79–2.7 | 0.22     |
| APN metastasis             | 3.3       | 1.4–7.4  | 0.0052   |

As another topic, it was reported that elevated postoperative CEA—especially within the first 12 months after surgery—is an important indicator of recurrence of colon cancer. In this study, the blood levels of CEA were followed for 5 years, which helped to indicate when to perform additional tests to detect the recurrence of colorectal cancer. Therefore, it is thought that routine postoperative CEA measurement should be recommended.
left-sided colon cancers\(^\text{23}\); however, we did not consider the location in this analysis because the number of the high-risk stage III patients with APN metastasis was very small, and rectal cancers were excluded. Third, the adjuvant chemotherapy regimens were not identical, and the percentage of patients who received postoperative chemotherapy was relatively low, which may have influenced the results to a degree and hindered an appropriate analysis.

In conclusion, even though the study population was limited to patients with high-risk stage III disease, APN metastasis might be an independent predictor of the prognosis, and not only the number of metastatic lymph nodes but also the location of the metastatic lymph nodes might be deemed important for the prognosis of colon cancer patients. Although the number of patients with APN metastasis is relatively small, their poor prognosis should not be ignored. Further data on APN metastasis may help provide a more detailed prediction of the prognosis of colon cancer patients, in addition to the information obtained through the TNM staging system. Since the prognosis of high-risk stage III patients tends to be worse if they have APN metastasis, it may be better to monitor them closely and not shorten the duration of adjuvant chemotherapy.

**Ethics approval.** This study was performed in line with the principles of the Declaration of Helsinki. This study protocol was approved by the Ethical Advisory Committee of Yokohama City University Medical Center and the institutional review board of each participating hospital before the study was initiated. Yokohama City University Medical Center, Yokohama City University Hospital, and Yokosuka Kyosai Hospital participated in this study.

**Consent for participate and publication.** Due to the retrospective nature of the study, written informed consent was not obtained. We used the opt-out approach to disclose the study information. We obtained an “informed consent waiver” from the Ethical Advisory Committee of Yokohama City University Medical Center.

Received: 11 August 2021; Accepted: 24 January 2022
Published online: 08 February 2022

**References**

1. Hashiguchi, Y. et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. *Int. J. Clin. Oncol.* **25**(1), 1–42. [https://doi.org/10.1007/s10147-019-01485-z](https://doi.org/10.1007/s10147-019-01485-z) (2020).
2. Japanese Society of Cancer of the C and Rectum, Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma: the 3d English edition[secondary publication]; *J. Annu Rectum Colon* **3**(4), 175–195. [https://doi.org/10.23922/jarc.2019-018](https://doi.org/10.23922/jarc.2019-018) (2019).
3. Kawada, H., Kurita, N., Nakamura, F., Kawamura, J., Hasegawa, S., Koteke, K., Sugihara, K., Fukuhara, S., & Sakai, Y. Incorporation of apical lymph node status into the seventh edition of the TNM classification improves prediction of prognosis in stage III colonic cancer. *Br. J. Surg.* **101**(9):1143–1152 (2014).
4. Kang, J., Hur, H., Min, B. S., Kim, N. K. & Lee, K. Y. Prognostic impact of inferior mesenteric artery lymph node metastasis in colorectal cancer. *Ann. Surg. Oncol.* **18**(3), 704–710. [https://doi.org/10.1245/s10434-010-1291-x](https://doi.org/10.1245/s10434-010-1291-x) (2011).
5. Malassagne, B. et al. Relationship of apical lymph node involvement to survival in resected colon carcinoma. *Dis. Colon Rectum* **36**(7), 645–653. [https://doi.org/10.1097/01.DCR.00006438591](https://doi.org/10.1097/01.DCR.00006438591) (1993).
6. Huh, J. W., Kim, Y. J. & Kim, H. R. Distribution of lymph node metastases is an independent predictor of survival for sigmoid colon and rectal cancer. *Ann. Surg. Oncol.* **25**(1), 70–78. [https://doi.org/10.1097/SLA.0b013e3182378516](https://doi.org/10.1097/SLA.0b013e3182378516) (2012).
7. Peng, J. et al. Prognostic significance of apical lymph node metastasis in patients with node-positive rectal cancer. *Colorectal Dis.* **15**(1), e13–20. [https://doi.org/10.1111/coadi.12055](https://doi.org/10.1111/coadi.12055) (2013).
8. Yeom, S. S., Lee, S. Y., Kim, C. H., Kim, H. R. & Kim, Y. J. The prognostic effect of adjuvant chemotherapy in the colon cancer patients with solitary lymph node metastasis. *Int. J. Colorectal Dis.* **34**(6), 1483–1490. [https://doi.org/10.1007/s00384-019-03346-7](https://doi.org/10.1007/s00384-019-03346-7) (2019).
9. Kanemitsu, Y., Komori, K., Kimura, K. & Kato, T. D3 lymph node dissection in right hemicolectomy with a no-touch isolation technique in patients with colon cancer. *Dis. Colon Rectum* **56**(7), 815–824. [https://doi.org/10.1097/DCR.0b013e3182919093](https://doi.org/10.1097/DCR.0b013e3182919093) (2013).
10. Kobayashi, H. et al. Clinical significance of lymph node ratio and location of nodal involvement in patients with right colon cancer. *Dig. Surg.* **28**(3), 190–197. [https://doi.org/10.1159/000329366](https://doi.org/10.1159/000329366) (2011).
11. Yi, J. W. et al. Apical-node metastasis in sigmoid colon or rectal cancer: Is it a factor that indicates a poor prognosis after high ligation? *Int. J. Colorectal Dis.* **27**(1), 81–87. [https://doi.org/10.1007/s00384-011-1271-z](https://doi.org/10.1007/s00384-011-1271-z) (2012).
12. Suzuki, O. et al. Number of lymph node metastases is better predictor of prognosis than level of lymph node metastasis in patients with node-positive colon cancer. *J. Am. Coll. Surg.* **202**(5), 732–736. [https://doi.org/10.1016/j.jamcollsurg.2006.02.007](https://doi.org/10.1016/j.jamcollsurg.2006.02.007) (2006).
13. Huang, Q. et al. Prognostic significance of D3 lymph node for survival in patients with colorectal cancer. *J. Surg. Res.* **239**, 156–165. [https://doi.org/10.1016/j.jss.2019.01.018](https://doi.org/10.1016/j.jss.2019.01.018) (2019).
14. André, T. et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): Final results from a prospective, pooled analysis of six randomised, phase 3 trials. *Lancet Oncol.* **21**(12), 1620–1629. [https://doi.org/10.1016/s1470-2045(20)30527-1](https://doi.org/10.1016/s1470-2045(20)30527-1) (2020).
15. Katuka, M. et al. Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colorectal cancer. *ESMO Open* **3**(3), e003543. [https://doi.org/10.1136/esmoopen-2018-000354](https://doi.org/10.1136/esmoopen-2018-000354) (2018).
16. Tsai, H. L. et al. Apical Lymph Nodes in the Distant Metastases and Prognosis of Patients with Stage III Colorectal Cancer with Adequate Lymph Node Retrieval Following FOLLOW Adjunct Chemotherapy. *Pathol. Oncol. Res.* **25**(3), 905–913. [https://doi.org/10.1007/s12253-017-0381-5](https://doi.org/10.1007/s12253-017-0381-5) (2019).
17. Tang, K. et al. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. *J. Am. Coll. Surg.* **180**(6), 705–712 (1995).
18. Wang, L. M. et al. The role of apical lymph node metastasis in right colon cancer. *Int. J. Colorectal Dis.* **35**(10), 1887–1894. [https://doi.org/10.1007/s00384-020-03661-4](https://doi.org/10.1007/s00384-020-03661-4) (2020).
19. Chen, H. et al. Factors influencing apical node metastasis in colorectal cancer patients treated with laparoscopic radical resection with D3 lymphadenectomy: results from two centers in China. *Surg. Today* **45**(5), 569–575. [https://doi.org/10.1007/s00595-014-1013-2](https://doi.org/10.1007/s00595-014-1013-2) (2015).
20. Wang, L. et al. Prognostic utility of apical lymph node metastasis in patients with left-sided colorectal cancer. *In Vivo* **34**(5), 2981–2989. [https://doi.org/10.21873/inivo.12129](https://doi.org/10.21873/inivo.12129) (2020).
21. Lange, M. M., Buunen, M., van de Velde, C. J. & Lange, J. F. Level of arterial ligation in rectal cancer surgery: Low tie preferred over high tie. A review. Diseases of the Colon Rectum 51(7), 1139–1145. https://doi.org/10.1007/s10350-008-9328-y (2008).
22. Konishi, T. et al. Association of preoperative and postoperative serum carcinoembryonic antigen and colon cancer outcome. JAMA Oncol. 4(3), 309–315. https://doi.org/10.1001/jamaoncol.2017.4420 (2018).
23. Kim, C. H., Huh, J. W., Kim, H. R. & Kim, Y. J. Prognostic comparison between number and distribution of lymph node metastases in patients with right-sided colon cancer. Ann. Surg. Oncol. 21(4), 1361–1368. https://doi.org/10.1245/s10434-013-3426-3 (2014).
24. Benedix, F. et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis. Colon Rectum 53(1), 57–64. https://doi.org/10.1007/dcr.0b013e3181c703a4 (2010).

Author contributions
K.I. and J.W. wrote the main manuscript text and K.I. and J.W. prepared figures 1-2. All authors collected the data and reviewed the manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to J.W.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022